INHIBITION OF THE NT-3:TRKC BOUND AND ITS APPLICATION TO THE TREATMENT OF CANCER SUCH AS NEUROBLASTOMA

摘要

The subject matter of the present disclosure relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compounds to interact with neurotrophin 3 (NT-3 or NT3), to the extracellular domain or TrkC receptor and/or to inhibit the dimerization of the intracellular domain of the TrkC receptor expressed in tumor cells, particularly in neuroblastoma. The disclosure also relates to a method for predicting the presence of metastatic cancer or a bad prognosis cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of neurotrophin 3. The disclosure further comprises kits and compounds as a medicament for the treatment of neuroblastoma or cancer overexpressing neurotrophin 3 by the tumor cells.

主权项

1. A method of treatment of cancer for inducing the apoptosis or the cell death of tumor cells which have acquired the selective advantage to escape neurotrophin 3 dependence receptors induced apoptosis in a patient in need thereof, comprising administering to the patient a compound able to inhibit this selective advantage in a tumor cell in said patient by inhibiting the interaction between neutrophin-3 and the TrkC receptor selected among the group consisting of
a soluble TrkC receptor comprising at least the extracellular domain of the TrkC receptor capable of binding to neurotrophin 3; a monoclonal or polyclonal antibody directed specifically against neurotrophin 3 or the TrkC receptor.